survival rates

lung cancer

Biotech

AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail

AstraZeneca and Daiichi have shared the OS data with regulators that are reviewing filings for approval of Dato-DXd.

Nick Paul Taylor Sep 10, 2024 6:00am

FDA Building 2

Differences in survival spark FDA hold on Oncopeptides' drug

Jul 8, 2021 8:05am

red blood cells

Takeda takes on multiple myeloma outcomes study, as Ninlaro flounders

Aug 31, 2016 8:00am